Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 7/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 6/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3524509 | 1.00 | OPRM1 (0.36) | OPRM1OPRD1KCNH2SLC6A2SCN5A | |
| SCHEMBL12012239 | 0.92 | OPRM1 (0.38) | OPRM1OPRD1KCNH2SLC6A2SCN5A | |
| SCHEMBL12012238 | 0.82 | CHRM2 (0.34) | OPRM1OPRD1KCNH2SLC6A2SCN5A | |
| SCHEMBL3524229 | 0.78 | KCNH2 (0.33) | KCNH2SCN5ACHRM2CHRM1 | |
| SCHEMBL3524225 | 0.78 | KCNH2 (0.33) | KCNH2SCN5ACHRM2CHRM1 | |
| SCHEMBL3524223 | 0.78 | KCNH2 (0.33) | KCNH2SCN5ACHRM2CHRM1 | |
| SCHEMBL3523921 | 0.76 | KCNH2 (0.58) | KCNH2SCN5A | |
| SCHEMBL3523920 | 0.76 | KCNH2 (0.58) | KCNH2SCN5A | |
| SCHEMBL3520222 | 0.72 | CHRM2 (0.45) | EPHX2CHRM2CHRM1 | |
| SCHEMBL3520227 | 0.72 | CHRM2 (0.45) | EPHX2CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252810-B2 | Bicycloamine derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-08-28 | — | — | US | disclosed |
| US-20100331310-A1 | BICYCLOAMINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-12-30 | — | — | US | disclosed |
| EP-2241567-A1 | BICYCLOAMINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2010-10-20 | — | — | EP | disclosed |
| US-20090270369-A1 | BICYCLOAMINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331310-A1 | BICYCLOAMINE DERIVATIVES | SCN1B, KCNJ2, KCNH2 | OPRM1 156/4885OPRD1 105/4885KCNH2 3/4885 |
| US-20090270369-A1 | BICYCLOAMINE DERIVATIVES | SCN1B, KCNJ2, KCNH2 | OPRM1 156/4885OPRD1 105/4885KCNH2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.